Sanofi Recalls Insulin Pens, Sarclisa Over Cold Chain

Health Canada posted two separate recall advisories for Sanofi-Aventis Canada on 25 September — one for insulin pens and cartridges, a second for the multiple myeloma antibody Sarclisa (isatuximab) — both citing the same underlying failure: shipments that may have frozen in transit. Frozen insulin and frozen biologics share the same risk profile. The protein can lose potency without any visible change to the product, which is why Health Canada is pulling both rather than waiting for a confirmed clinical event.

Two products, one cold-chain failure

The insulin recall is the better-documented of the two. Health Canada's notice states 1,043 units of Sanofi insulin pens and cartridges — shipped to about 80 sites nationwide across two windows, 13 through 15 July and 10 through 13 August 2026 — may have been exposed to freezing temperatures during shipping. That represents a small fraction, under 1%, of the units Sanofi distributed in Canada over the same period. The company's public advisory, carried through Newswire.ca, instructs pharmacies and clinics holding affected stock to stop dispensing it and arrange for replacement, and tells any patient who may have already used potentially frozen insulin to watch their blood sugar closely, since reduced potency can translate into under-dosing and hyperglycemia.

A second Health Canada recall notice, also dated 25 September, covers a separate Sanofi product: Sarclisa (isatuximab), the CD38-targeted monoclonal antibody used in multiple myeloma regimens. The notice states that “a limited number of Sarclisa single use vials may have been frozen during shipment” — the same underlying failure mode as the insulin recall, though Health Canada's published notice for Sarclisa does not specify how many vials, which sites received them, or when they shipped. Isatuximab, like insulin, is a protein-based biologic, and freezing during transport can compromise a monoclonal antibody's structure and potency in ways that are not visible on inspection.

A distribution problem, not a formulation one

Neither notice describes a manufacturing defect in the products themselves. Both point to the cold chain — the temperature-controlled logistics between Sanofi's distribution centers and the pharmacies, clinics and hospitals that received the shipments — as the point of failure. For QA and distribution teams, that puts the incident in a familiar category: a temperature excursion during transit rather than a lot-release or formulation problem, the kind of failure that traces back to carrier qualification, temperature-monitoring devices, and the handling instructions given to couriers rather than to the manufacturing line itself. Health Canada's notices do not identify a root cause for how the excursion occurred, and neither recall has a confirmed U.S. counterpart; both actions currently appear to be limited to the Canadian market.

Frequently asked questions

What did Health Canada recall?

Two separate Sanofi-Aventis Canada products, in advisories both dated 25 September 2026: certain insulin pens and cartridges (1,043 units shipped to roughly 80 pharmacies, clinics and hospitals), and a limited number of Sarclisa (isatuximab) single-use vials. Both notices cite possible freezing during shipping.

Why does freezing matter for these products?

Insulin and isatuximab are biologic protein formulations. Freezing can degrade a biologic's structure and reduce its potency even after it thaws and looks unchanged. For insulin, reduced potency risks under-dosing and hyperglycemia.

When were the affected units shipped?

The insulin advisory states affected shipments went out 13–15 July and 10–13 August 2026, to roughly 80 sites — under 1% of total units distributed in that window. The Sarclisa notice does not specify shipment dates or a unit count.

What should a pharmacy or patient do?

Health Canada instructs sites holding affected insulin stock to stop dispensing it and arrange replacement, and tells patients who may have used potentially frozen insulin to monitor blood sugar closely and contact a health-care provider with concerns. Both recalls are limited to Canada; no matching U.S. FDA action has been identified.